Related Experiment Video
Updated: Nov 21, 2025

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
[Personalized treatment concepts for arterial hypertension]
Katharina Lechner1,2, Heribert Schunkert3,4
1Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technische Universität München, Lazarettstraße 36, 80636, München, Deutschland.
Abstract:
Arterial hypertension is the most important risk factor for cardiovascular diseases. Arterial hypertension is diagnosed when reproducible office resting blood pressure values are 140 mm Hg or more systolic and/or 90 mm Hg or more diastolic. A recent alternative is to base the diagnosis of hypertension on ambulatory 24 h blood pressure monitoring (ABPM) and/or home blood pressure monitoring (HBPM) if feasible. Nonpharmacological and pharmacological strategies of blood pressure management are available. Treatment decisions should involve a shared decision-making process and pharmacological agents as well as lifestyle recommendations should be tailored to the needs and comorbidities of each individual patient in a personalized approach. The target values depend on age and comorbidities. Despite clear recommendations as depicted in pertinent guidelines, blood pressure control remains inadequate in the majority of hypertensive patients. The continuous improvement of perception, diagnostics and treatment thus remain high priorities in healthcare systems worldwide. The aim of this CME article is to provide a perspective on recent developments in the management of arterial hypertension.
Related Concept Videos
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension V: Nursing Management
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Peripheral Artery Disease III: Interprofessional Care
Atherosclerosis III: Management

